Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Therapeutic Drug Monitoring
|
May 22, 2002
Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication
Theodor W May, Bernhard Rambeck, Uwe Jürgens
Therapeutic Drug Monitoring
|
November 26, 2003
Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication
Theodor W May, Bernhard Rambeck, Uwe Jürgens
Clinical Pharmacokinetics
|
September 10, 2003
Clinical pharmacokinetics of oxcarbazepine
Theodor W May, Elisabeth Korn-Merker, Bernhard Rambeck
Therapeutic Drug Monitoring
|
September 28, 2002
Does lamotrigine influence valproate concentrations?
Mihaela-Irina Mataringa, Theodor W May, Bernhard Rambeck
Therapeutic Drug Monitoring
|
November 29, 2007
Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication
Theodor W May, Bernhard Rambeck, Roland Neb, et al.
Pharmaceutical Research
|
September 5, 2009
The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins
Carlos Luna-Tortós, Bernhard Rambeck, Uwe H Jürgens, et al.
Epilepsy Research
|
May 6, 2011
Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions--first clinical experience
Annika Sattler, Marion Schaefer, Theodor W May, et al.
Epilepsy & Behavior : E&B
|
July 24, 2012
Symptoms and course of intoxication with mesuximide--a case report
Robert Hoepner, Theodor W May, Bernhard Rambeck, et al.
Therapeutic Drug Monitoring
|
March 9, 2011
Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication
Theodor W May, Rainer Boor, Bernhard Rambeck, et al.
Epileptic Disorders : International Epilepsy Journal with Videotape
|
September 16, 2005
Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy
Walter Fröscher, Katja R Schier, Markus Hoffmann, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Therapeutic Drug Monitoring
|
May 22, 2002
Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication
Theodor W May, Bernhard Rambeck, Uwe Jürgens
Therapeutic Drug Monitoring
|
November 26, 2003
Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication
Theodor W May, Bernhard Rambeck, Uwe Jürgens
Clinical Pharmacokinetics
|
September 10, 2003
Clinical pharmacokinetics of oxcarbazepine
Theodor W May, Elisabeth Korn-Merker, Bernhard Rambeck
Therapeutic Drug Monitoring
|
September 28, 2002
Does lamotrigine influence valproate concentrations?
Mihaela-Irina Mataringa, Theodor W May, Bernhard Rambeck
Therapeutic Drug Monitoring
|
November 29, 2007
Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication
Theodor W May, Bernhard Rambeck, Roland Neb, et al.
Pharmaceutical Research
|
September 5, 2009
The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins
Carlos Luna-Tortós, Bernhard Rambeck, Uwe H Jürgens, et al.
Epilepsy Research
|
May 6, 2011
Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions--first clinical experience
Annika Sattler, Marion Schaefer, Theodor W May, et al.
Epilepsy & Behavior : E&B
|
July 24, 2012
Symptoms and course of intoxication with mesuximide--a case report
Robert Hoepner, Theodor W May, Bernhard Rambeck, et al.
Therapeutic Drug Monitoring
|
March 9, 2011
Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication
Theodor W May, Rainer Boor, Bernhard Rambeck, et al.
Epileptic Disorders : International Epilepsy Journal with Videotape
|
September 16, 2005
Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy
Walter Fröscher, Katja R Schier, Markus Hoffmann, et al.
Page
of 2